High Frequency of Severe Hyperglycemia Observed During Intensive Hematologic Care: A Prospective Study Using Continuous Glucose Monitoring
Authors' conclusion
These findings emphasize the potential and importance of glucose monitoring with CGM for improved and earlier detection of hyperglycemia, in this patient population, which seems feasible. Our results suggest a need for further studies into CGM as method to optimize glucose levels, which could improve outcomes in patients receiving intensive hematologic care.
Study context
- Population
- Patients receiving CAR T-cell therapy or allogeneic or autologous stem cell transplantation; 71% male, median age 64 (IQR 58–68) years, 10% with diabetes
- Participants
- 60 patients
- Exposure
- Continuous glucose monitoring (CGM) vs point-of-care (POC) glucose measurements
- Outcome
- Dysglycemia identified by CGM during intensive hematologic care
Main finding
As reported in the abstract
Hyperglycemia (glucose >10 mmol/L), % of patients
93%
Of those with hyperglycemia, no history of diabetes
90%
Severe hyperglycemia (glucose >13.1 mmol/L)
38%
Observational data: associations, not effects.
Further findings
Events
| Outcome | CGM | POC |
|---|---|---|
| Detection of hyperglycemia (>10 mmol/L), CGM vs POC | 1060 | 124 |
- Detection of hyperglycemia (>10 mmol/L), CGM vs POC — Detected earlier with CGM, hours (IQR 0.7-4.0)
- 2.8
Hyperglycemia and prolonged hospitalization
- CAR T-cell treatment: β
- 0.19 (95% CI 0.04-0.35)
- Autologous stem cell transplantation: β
- 0.16 (95% CI 0.01-0.32)
Accuracy of CGM vs POC
- Mean absolute relative difference
- 21.5%
- Measurements in Clarke error grid zone A + B
- 99.8%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →